hENT1 (human equilibrative nucleoside transporter 1) is inhibited by nanomolar concentrations of various structurally distinct coronary vasodilator drugs, including dipyridamole, dilazep, draflazine, soluflazine and NBMPR (nitrobenzylmercaptopurine ribonucleoside). When a library of randomly mutated hENT1 cDNAs was screened using a yeast-based functional complementation assay for resistance to dilazep, a clone containing the W29G mutation was identified. Multiple sequence alignments revealed that this residue was highly conserved. Mutations at Trp 29 were generated and tested for adenosine transport activity and inhibitor sensitivity. 
INTRODUCTION
NTs (nucleoside transporters) are involved in the uptake and salvage of extracellular nucleosides, the metabolic precursors of nucleotides and nucleic acids [1] [2] [3] [4] . NTs also regulate the effective concentration of adenosine, which binds cell-surface G-protein-coupled receptors that modulate important neurological and cardiovascular processes [5, 6] . The intracellular concentrations of many nucleoside analogue antineoplastic and antiviral agents are also dependent on NTs [7, 8] . It has been shown that the abundance of hENT1 (human equilibrative nucleoside transporter 1) is an important determinant of response of patients with pancreas adenocarcinoma to treatment with the cytidine analogue gemcitabine [9] .
The ENT (equilibrative nucleoside transporter) family [SLC29 (solute carrier family 29)] consists of many transporters from various species that share a common 11 TM (transmembrane segment) topology [10] . Most ENT members mediate equilibrative transport of nucleosides and, in some cases, nucleobases across biological membranes, although some members display proton-coupled transport [11] . ENT family members differ with respect to their functional properties. NBMPR (nitrobenzylmercaptopurine ribonucleoside {6- [(4-nitrobenzyl) -thiol]-9-β-D-ribofuranosyl purine}) has been used to functionally distinguish the two major plasma membrane ENTs of mammalian cells as equilibrative-sensitive (es) or equilibrative-insensitive (ei). The es transporter binds NBMPR with high affinity (K d = 0.1-1 nM), and in humans is hENT1 (SLC29A1), whereas the ei transporter binds NBMPR at micromolar concentrations and in humans is hENT2 (SLC29A2) [12, 13] . Both hENT1 and hENT2 are also inhibited by the coronary vasodilator drugs dipyridamole, dilazep, draflazine and soluflazine, although hENT2 is several orders of magnitude less sensitive to these agents [14] [15] [16] .
hENT1 and hENT2 are functionally similar in that they are predominantly broadly selective, transporting both purine and pyrimidine nucleosides, in contrast with some other family members such as the Leishmania donovani NTs (LdNTs), which display non-overlapping permeant selectivities, transporting either pyrimidine nucleosides and adenosine (LdNT1.1 and LdNT1.2), or exclusively inosine and guanosine (LdNT2) [12, [17] [18] [19] . Identification of the molecular determinants of inhibitor sensitivity and permeant selectivity will provide important insights into ENT structure and function.
Several molecular determinants of hENT inhibitor sensitivity have been identified. We have reported previously that residue 33, predicted to lie at the C-terminal extracellular end of TM1 in hENT1 and hENT2, is a functionally important component of the Abbreviations used: CMM, complete minimal medium; CfNT, Crithidia fasciculata nucleoside transporter; ENT, equilibrative nucleoside transporter; ei, equilibrative-insensitive; es, equilibrative-sensitive; GLU, glucose; hENT, human ENT; LdNT, Leishmania donovani nucleoside transporter; MTX, methotrexate; NBMPR, nitrobenzylmercaptopurine ribonucleoside; NT, nucleoside transporter; rENT, rat ENT; SAA, sulfanilamide; SLC, solute carrier; TM, transmembrane segment. 1 These authors contributed equally to this work. 2 To whom correspondence should be addressed (email carol.cass@cancerboard.ab.ca).
binding sites for dilazep, dipyridamole and nucleosides [15, 20] . In addition, Leu 442 in TM11 of hENT1 was shown to play a role in dipyridamole interactions when Met 33 is first mutated [21] . Several residues within TM2 (Met 89 and Leu 92 ), TM4 (Gly 154 and Ser 160 ) and TM5 (Gly 179 ) of hENT1 have been shown to be involved in both the permeant translocation pathway and NBMPR binding [22] [23] [24] [25] . Recently, Asn 338 in TM8 of hENT1 was shown to be an important determinant of draflazine and soluflazine binding to hENT1 [26] .
The aim of the present study was to identify additional amino acid residues of hENT1 involved in binding of ENT inhibitors as well as determine their importance for physiological nucleoside transport. The random mutagenesis and functional complementation screening methods that were previously employed in the identification of Met 33 , Asn   338 and Leu 442 of hENT1 [15, 21] identified Trp 29 as a previously unrecognized residue involved in inhibitor binding. Mutants were generated at Trp 29 based on their homologies with other ENT family members and tested for adenosine transport activity and inhibitor sensitivities. hENT1-W29T, which represents a mutation to the corresponding residue in the inosine/guanosine transporter LdNT2, displayed a selective loss of pyrimidine nucleoside (uridine and cytidine) transport activity. The functional characteristics of W29T, L442I (which displayed a selective reduction in adenosine, but not uridine transport activity [21] ) and the double mutant W29T/L442I were investigated in detail. A helical wheel projection of TM1 was generated to assess the possibility that Trp 29 may line the permeant translocation pathway and/or inhibitor binding site(s). Taken together, the results of the present study suggest that Trp 29 forms part of, or lies close to, overlapping permeant and inhibitor-binding sites.
EXPERIMENTAL

Strains and media
KY114 (MATα, gal, ura3-52, trp1, lys2, ade2, hisd2000) was the parental yeast strain used to generate KTK, which produces recombinant herpes simplex thymidine kinase [27] , and fui1::TRP1, which contains a disruption in the gene encoding the endogenous uridine permease (FUI1) [28] . Other strains were generated by transformation of the yeast/Escherichia coli shuttle vector pYPGE15 [containing the constitutive PGK (phosphoglycerate kinase) promoter] [29] into KTK and fui1::TRP1 using a standard lithium acetate method [30] . Yeast strains were maintained in CMM (complete minimal medium) containing 0.67 % yeast nitrogen base (Difco), amino acids (as required to maintain auxotrophic selection) and 2 % GLU (glucose) (CMM/GLU). Agar plates contained CMM with various supplements and 2 % agar (Difco). Plasmids were propagated in E. coli strain TOP10F (Invitrogen) maintained in Luria broth with ampicillin (100 μg/ml).
Plasmid construction and random mutagenesis
The hENT1 reading frame was subcloned into pYPGE15 to generate pYPhENT1 as described previously [15] . Random mutagenesis of pYPhENT1 was performed by propagating the plasmid in the XL-1 RED mutator strain of E. coli (Stratagene) for 30-45 generations to obtain ∼ 1 mutation per cDNA, according to the procedure of Greener et al. [31] . Point mutations resulting in various amino acid changes of the identified residues were generated using the QuikChange ® XL site-directed mutagenesis kit (Stratagene).
Phenotypic complementation and screening of mutants
The complementation assay was based on the ability of recombinant hENT1 produced in yeast to salvage exogenously supplied thymidine under conditions of TMP starvation [32] . In brief, KTK cells transformed with pYPhENT1 using a lithium acetate procedure [30] were plated directly on to CMM/GLU plates containing MTX (methotrexate) at 50 μg/ml and SAA (sulfanilamide) at 6 mg/ml (CMM/GLU/MTX/SAA) at a pH of 7.0. Colonies formed with an efficiency of ∼ 10 5 transformants/ μg of DNA after incubation at 30
• C for 3.5 days in the presence of 10 μM thymidine, and complementation was prevented when 10 μM dilazep was also present. Mutated pYPhENT1 (20 μg) was transformed into KTK cells, which were then plated on to CMM/GLU/MTX/SAA with 10 μM thymidine and 10 μM dilazep and incubated at 30
• C for 3.5 days. The mutant hENT1 cDNAs were amplified from the yeast colonies by PCR, subcloned back into non-mutated pYPGE15 and sequenced.
Nucleoside transport in Saccharomyces cerevisiae
The uptake of [ 3 H]nucleosides (Moravek Biochemicals) into yeast was measured as described previously [33, 34] For kinetic analysis of nucleoside transport in hENT1 and hENT1 mutants, single time points of 10 min were used to estimate initial rates of transport for all hENT1 constructs, except for the low-transport-activity mutant W29T/L442I for which single time points of 45 min were used. Yeast cells were exposed to nucleosides in the concentration range 0.1-500 μM. Uptake rates were considered to be initial rates because uridine and adenosine uptake by yeast cells producing recombinant hENT1 was shown previously to be a linear function of time for up to 60 min [20] , evidently because of rapid trapping inside cells via phosphorylation. The kinetics of transport of pyrimidine nucleosides and guanosine by W29T and W29T/L442I could not be determined due to the low observed transport activities.
For investigation of inhibitor concentration-effect relationships, the yeast suspensions were first incubated for 15-30 min with the inhibitor to allow equilibration of the inhibitor with its binding sites before the addition of radiolabelled permeant as described previously [15] . For inhibition of transport by unlabelled nucleosides, the inhibitory and radiolabelled nucleosides were added simultaneously and the permeants used were as follows: 50 values determined from concentration-effect curves were converted into K i values using the Cheng-Prusoff equation [35] :
was the concentration of nucleoside permeant (1 μM) and apparent K m values were determined from kinetic experiments (see Table 2 ).
For time course experiments, uptake of a particular radiolabelled nucleoside at 1 μM was measured at 1, 5, 10 and 20 min, and mediated uptake was calculated from the difference in uptake of yeast cells incubated with or without 100 μM dilazep. Despite the involvement of Trp 29 in dilazep binding (see Figure 2 ), 100 μM dilazep was sufficient to completely inhibit mediated transport by all of the mutants investigated. Initial rates of uptake were calculated from the slope of the linear component of the time course. For all transport experiments, yeast protein content was measured by the Bio-Rad protein assay [36] .
RESULTS
Random mutagenesis and screening
Growth of yeast cells with MTX and SAA in the medium depletes intracellular TTP pools and leads to inhibition of DNA synthesis and growth arrest [37] . Although yeast cells lack endogenous thymidine transport systems [38] , production of recombinant hENT1 in KTK yeast cells, which produce herpes simplex thymidine kinase, allows for salvage from the external medium of thymidine, which is phosphorylated to TMP by thymidine kinase, thereby enabling DNA synthesis and growth [32] . When a nucleoside transport inhibitor is added to the medium, thymidine salvage through hENT1 is blocked, providing a functional complementation assay for hENT1 mutants with reduced affinities for transport inhibitors. In the present study, the yeast expression plasmid pYPhENT1 was randomly mutated by propagation in the E. coli mutator strain XL-1 RED (Stratagene) and transformed into KTK yeast under complementation conditions in the presence of inhibitory concentrations of the nucleoside transport inhibitor dilazep. Although the vast majority of dilazep-resistant clones isolated contained previously identified mutations at the codon for methionine at residue 33 [15] , a new mutation resulting in the conversion of tryptophan into glycine at residue 29 was also identified.
Multiple sequence alignments of TM1
Like Met 33 , which was shown previously to be important in binding of various ENT1 inhibitors and nucleosides [15, 20] , Trp 29 is located in TM1. To assess the level of conservation of Trp 29 , sequence alignment analyses were performed for TM1 with 43 different ENT family members from a variety of different organisms; the alignment of a few select sequences is shown in Figure 1 . Trp 29 was conserved in 65 % of the ENTs analysed, suggesting that this residue may play an important structural and/or functional role.
Effects of hENT1 Trp 29 mutations on sensitivity to transport inhibitors
To determine the contributions of Trp 29 to interactions of hENT1 with several ENT transport inhibitors, a series of mutations at residue 29 were generated based, in part, on the identities of corresponding residues in other ENT family members. Concentration-effect relationships for inhibition of adenosine transport were determined for NBMPR, soluflazine, draflazine, dipyridamole and dilazep. The resulting IC 50 values for W29G, W29C, W29A, W29Y, W29V and W29T mutants are presented in Figure 2 .
NBMPR and soluflazine
Although the absolute values differed (NBMPR soluflazine), the trends in the IC 50 values obtained for NBMPR and soluflazine Protein sequences for 43 ENT family members were obtained from GenBank ® and subjected to multiple sequence alignment with DNAMAN version 4.03 software using the BLOSUM 62 substitution matrix. Shown here are sequences from AAC51103 (hENT1), AAF78452 (mouse; mENT1), AAB88049 (rat; rENT1), AAS99848 (canine; cENT1), AAC39526 (hENT2), AAM46663 (Caenorhabditis elegans; CeENT1), AAC32597 (LdNT1.1), AAF74264 (LdNT2), AAG22610 (CfNT1) and AAG22611 (CfNT2). Residues that were identical in 50 % of sequences are shaded. The positions corresponding to Trp 29 (the present study) and Met 33 [15] of hENT1 are indicated with arrowheads.
were remarkably similar ( Figure 2 ). The Trp 29 mutants displayed a wide range of IC 50 values, with aromatic residues having the lowest IC 50 values, followed by valine, threonine, alanine, cysteine and glycine. W29G displayed IC 50 values that were 120-and 150-fold larger than those of wild-type for NBMPR and soluflazine respectively, suggesting that amino acid side-chain type and/or volume at residue 29 was critical for high-affinity interactions with NBMPR and soluflazine. The IC 50 values observed for dipyridamole inhibition of adenosine transport were consistently ∼ 50 % of the values obtained for inhibition of uridine transport (results not shown), even though dipyridamole is a purely competitive inhibitor of hENT1 transport of both adenosine and uridine [21] . The reasons for these small discrepancies are unclear, but the relative differences in dipyridamole sensitivities for the mutants were highly consistent with the data obtained using uridine as the test permeant.
Dilazep
All Trp 29 mutations significantly increased IC 50 values for dilazep inhibition of adenosine transport. The threonine and glycine substitutions were the least deleterious to dilazep binding, with IC 50 values 22-and 30-fold larger than that of wild-type hENT1. The largest increase was observed for the W29V mutation, which exhibited an IC 50 value that was 300-fold larger than that of wildtype. These results suggested that tryptophan at residue 29 was critical for high-affinity binding of dilazep by hENT1 since all of the mutations at this residue significantly impaired inhibitor interactions. 
Effects of hENT1 Met 33 mutations on sensitivity to soluflazine and draflazine
Met 33 , which is also predicted to be part of TM1, was previously shown to be a critical determinant of hENT1 and hENT2 interactions with dilazep and dipyridamole, but not NBMPR [15] . In the present study, we investigated whether this residue also plays a role in draflazine and soluflazine interactions with hENT1. The concentration-effect relationships for inhibition by soluflazine of Met 33 mutants were examined using the same procedures as for the Trp 29 mutants (Figure 3 ). Met 33 mutations had no effect on the IC 50 values for draflazine (results not shown), whereas they exhibited altered IC 50 values for soluflazine. M33F and M33A displayed >10-fold higher IC 50 values than wild-type hENT1, whereas M33L displayed an IC 50 value that was 50 % of the wild-type value. These results suggest that the extended hydrophobic side chains of methionine and leucine at residue 33 are favoured for soluflazine interactions with hENT1.
To test the role of residue 33 in soluflazine interactions further, the corresponding residue (isoleucine) in rat ENT1 (rENT1) was also mutated because this transporter generally displays much higher IC 50 values for ENT inhibitors (Figure 3) . The I33M and I33L mutations both exhibited IC 50 values that were 20 % of that of wild-type rENT1. These results suggest that, in addition to dilazep and dipyridamole, residue 33 is an important determinant of sensitivity to soluflazine.
Effects of Trp 29 mutations in hENT1 on the concentration dependence of adenosine transport
The same series of Trp 29 mutants used to study inhibitor interactions were tested for their effects on adenosine transport.
Yeast cells producing recombinant hENT1 or one of the mutants were incubated in the presence of increasing concentrations of Table 1 . hENT1 displayed an apparent K m value of 19 + − 2 μM, indicating that recombinant hENT1 displayed a similar affinity for adenosine when produced in yeast as was observed in transfected mammalian cells [16] . For the Trp 29 mutants, replacement of tryptophan with the relatively smaller side chains of glycine, alanine, cysteine or valine reduced apparent V max values by >50 %, whereas replacement with tyrosine or valine resulted in 6.8-and 7.4-fold increased apparent K m values respectively (Table 1) . W29I was nonfunctional and was not analysed further. None of the mutants displayed transport efficiencies comparable with that of wildtype, suggesting that only a tryptophan residue at position 29 yielded efficient transport function by hENT1.
Rates of uptake for physiological nucleosides by hENT1 and hENT1 mutants
During preliminary studies, the W29T mutant displayed little, if any, uridine transport activity without a corresponding decrease in adenosine transport activity. In a previous study [21] , the L442I mutant in TM11 displayed a similar, although reciprocal, transport phenotype, having selectively lost much of its adenosine transport activity without a corresponding loss of uridine transport activity. The transport characteristics of W29T, L442I and W29T/L442I were therefore determined for several physiological nucleosides (Figure 4) .
W29T displayed uridine transport rates that were only 8 % of that of wild-type and mediated cytidine transport was undetectable, suggesting that the presence of threonine at residue 29 severely compromised transportability of pyrimidine nucleosides. In contrast, the transport rates of adenosine, inosine and guanosine were 42, 50 and 60 % respectively of that of wildtype. These data suggested that the W29T mutation had more deleterious effects on transport of pyrimidine nucleosides than of purine nucleosides. Cytidine and uridine rates of transport by L442I were 93 and >100 % of those of wild-type respectively, whereas guanosine, adenosine and inosine rates of transport were 8, 14 and 48 % of those of wild-type respectively. Although L442I substantially altered hENT1 purine nucleoside transport capacity, the mutation had relatively little effect on pyrimidine nucleoside transport capacity.
The W29T/L442I double mutant compromised transport of purine and pyrimidine nucleosides in that rates of uridine and cytidine uptake were 3 and 4 % of those of wild-type hENT1 respectively, and rates of guanosine, adenosine and inosine uptake were 6, 15 and 27 % of those of wild-type hENT1 respectively. The results suggest that the two mutations exerted their effects on nucleoside transport independently of each other.
Kinetic analyses of adenosine, inosine and uridine transport by hENT1 and hENT1 mutants
The kinetic characteristics of adenosine, inosine and uridine transport were determined for hENT1, W29T, L442I and W29T/L442I by assessing the dependence of initial transport rates on nucleoside concentrations. Mediated nucleoside uptake was determined by subtracting rates of uptake in the presence (background) of 100 μM dilazep from those in the absence (total transport) of dilazep. Apparent K m values, V max values and V max /K m ratios for adenosine, inosine and uridine are presented in Table 2 .
Similarly to what was found in the experiments shown in Table 1 , W29T displayed a 2.6-fold larger apparent K m value for adenosine than wild-type hENT1. The apparent V max values for wild-type hENT1 and W29T transport of adenosine were similar (1060 + − 210 and 850 + − 130 pmol/min per mg of protein respectively). The V max /K m ratio for wild-type hENT1 was 3.3-fold larger than that of W29T, suggesting that the W29T mutation decreased transport efficiency of hENT1 for adenosine. The experiments shown in Table 1 and Table 2 were performed using different frozen yeast stocks, which may explain the observed differences in Tables 1 and 2 For inosine transport by W29T and W29T/L442I, the apparent K m values were 2.5-fold larger than that of hENT1, suggesting that the mutant transporters' affinities for inosine significantly decreased compared with that of wild-type hENT1. W29T/L442I displayed a reduced transport capacity for inosine with an apparent V max value that was 48 % of that of wild-type hENT1. W29T and W29T/L442I displayed V max /K m ratios for inosine transport that were 37 and 20 % of those of wild-type respectively.
The kinetics of uridine transport by L442I indicated a 2-and 1.7-fold increase in the apparent K m and V max values respectively, when compared with wild-type, which was consistent with previously reported results for uridine transport by this mutant [21] . The increased apparent K m and V max values of uridine transport by L442I suggested that isoleucine at residue 442 reduced the apparent affinity, but increased transport capacity for uridine, yielding a similar V max /K m ratio. The experiments shown in Table 2 suggested that the W29T and L442I mutations compromised nucleoside transport of the permeants for which they retained notable transport activity (purine and pyrimidine nucleosides respectively). However, these changes were relatively minor compared with the reduction in pyrimidine nucleoside transport by W29T and purine nucleoside transport by L442I (Figure 4 ).
Apparent affinities of hENT1 and hENT1 mutants for physiological nucleosides
Although the W29T and L442I mutants displayed severely impaired transport of uridine and adenosine respectively, it was unclear whether these mutations also impaired nucleoside binding. The apparent affinities of W29T, L442I and W29T/L442I for nucleosides were determined using concentration-effect relationships for the inhibition of transport of a suitable Table 3 , with selected representative curves shown in Figure 5 . For the concentration-effect experiments involving W29T, 1 μM [ 3 H]adenosine was used as the radioactive permeant because W29T optimally transports adenosine. W29T displayed K i values that were 4.1-, 12-and >25-fold larger than those of wild-type hENT1 for thymidine, uridine and cytidine respectively, suggesting that the apparent affinities of W29T for pyrimidine nucleosides were decreased significantly. The K i values for guanosine, inosine and adenosine were 0.9-, 1.3-and 2.2-fold those of wild-type hENT1 respectively, suggesting that W29T maintained near-wild-type affinities for purine nucleosides.
For the concentration-effect experiments with L442I, 1 μM [ 3 H]uridine was used as the radioactive permeant because L442I displayed greater rates of uptake for uridine than adenosine. L442I exhibited K i values for uridine, cytidine and thymidine that were 1-, 1.5-and 1.6-fold those of wild-type hENT1 respectively, whereas the K i values for adenosine, guanosine and inosine were 6.7-, 3.2-and 1.9-fold larger than those of wild-type hENT1 respectively. For L442I, larger increases in K i values were observed for purine nucleosides than for pyrimidine nucleosides, suggesting that permeant binding to L442I was partially pyrimidine-nucleoside-selective. Since W29T and L442I were partially purine-and pyrimidinenucleoside-selective respectively, in terms of apparent affinities for nucleosides, the effects of combining these two mutations were determined. The permeant chosen for W29T/L442I was 1 μM [ 3 H]inosine since it had the largest rate of uptake by Table 3 .
the double mutant (Figure 4) . The K i values for thymidine, uridine and cytidine were 5.4-, 21-and >50-fold larger than those of wild-type hENT1 respectively, whereas the values for inosine, guanosine and adenosine were 2.6-, 4.8-and 9.3-fold larger than those of wild-type hENT1 respectively. W29T/L442I therefore exhibited characteristics of both mutations by displaying significantly reduced apparent affinities for both pyrimidine and purine nucleosides, although the effects on purine nucleoside transport were less severe than those on pyrimidine nucleoside transport.
DISCUSSION
Screening by random mutagenesis for hENT1 residues involved in dilazep interactions led to the identification of a mutation at Trp 29 . Trp 29 is within a region previously identified as being highly conserved, and therefore likely to be structurally and/or functionally important in ENT proteins [39] . In the present study, Trp 29 was shown to be a critical determinant of inhibitor sensitivity and adenosine transport efficiency (Table 1 , and Figures 2 and 3) . Furthermore, Trp 29 , together with the previously identified Leu 442 [21] , were shown to play important roles in nucleoside selectivity, suggesting that both residues contribute to the permeant translocation pathway.
Trp 29 affected sensitivity to all coronary vasodilator drugs tested, indicating the importance of this residue in inhibitor binding (Figure 2 ). Remarkably similar trends were observed for NBMPR and soluflazine, suggesting that the two inhibitors interacted with Trp 29 in a very similar manner. Large aromatic residues such as tryptophan and tyrosine were favourable The helical wheel projection, viewed from the extracellular side of the membrane, was generated using the HelixWheel program on the EXPASY molecular biology server and subsequently transposed on to a high-resolution helical wheel template. Based on multiple sequence alignments of 43 ENT sequences, residues indicated by darkened circles were hydrophilic (serine, threonine, aspartate, glutamate, asparagine, glycine, lysine or arginine) in 40 % of the sequences analysed and residues indicated by dark 'spokes' were identical in 40 % of the sequences analysed. Trp 29 (the present study) and Met 33 [15] are indicated with an asterisk.
to high-affinity interactions with NBMPR and soluflazine. Moreover, with the exception of W29C, the magnitude of the IC 50 values was inversely correlated with amino acid side-chain size. A common structural feature between soluflazine and NBMPR is the presence of aromatic fluorophenyl (soluflazine) or nitrobenzyl (NBMPR) groups, which, for NBMPR, have been shown to be critical for high-affinity binding (see Supplementary Figure 1 at http://www.BiochemJ.org/ bj/414/bj4140291add.htm) [40] . It is possible that Trp 29 interacted with these moieties via aromatic ring stacking interactions. Draflazine, which is structurally similar to soluflazine, also contains a fluorophenyl group but did not display similar trends to NBMPR or soluflazine, suggesting that draflazine may orient itself differently from soluflazine within the nucleoside transporter inhibitor binding site(s).
Dipyridamole and draflazine interactions were similarly affected by Trp 29 mutations, although there was no clear trend favouring any particular side-chain size or hydrophobicity, suggesting that Trp 29 mutations affected a common type of interaction between hENT1 and dipyridamole or draflazine. Similarly, Trp 29 mutations had profound effects on dilazep interactions without a clear trend in preference for any particular amino acid side-chain property. The helical wheel projection presented in Figure 6 suggests that Trp 29 is in close proximity to Met 33 , which was shown previously to be likely to interact directly with dipyridamole [20] . It is possible that the observed effects on dipyridamole interactions were due, in part, to the influence of Trp 29 on interactions between dipyridamole and residue 33.
The experiments shown in Figure 3 suggested that residue 33 was also involved in soluflazine interactions, although the effects of mutating this residue were less pronounced than reported previously for dipyridamole and dilazep [15] . Nonetheless, large aliphatic (leucine) and sulfur-containing (methionine) amino acid side chains were highly favoured at residue 33 for soluflazine interactions, and corresponding mutations conferred increased sensitivity to soluflazine in rENT1, which was similar to what was reported previously for dipyridamole [21] . These results suggest that residue 33 mutations affected a common mechanism of dipyridamole and soluflazine binding to hENT1 that could involve a direct hydrophobic contact, as was indicated by previous work [20] .
The experiments shown in Table 1 indicate that, although Trp 29 is not essential for transport function, it is an important determinant of adenosine transport efficiency, with small sidechain residues reducing the apparent V max values. It is possible that the observed changes in V max values are a consequence of reduced cell-surface delivery of hENT1 transporter proteins. In a previous study, we used [
3 H]NBMPR ligand-binding assays to quantify the number of functional cell-surface hENT1 transporters and calculate apparent turnover rates [26] . However, with the exception of W29Y, mutations at residue 29 impaired NBMPR binding >20-fold (Figure 2) , ruling out ligand-binding assays as an approach to quantification of cell-surface transporter protein. Biotinylation experiments to quantify cell-surface transporter protein were unsuccessful, possibly because of primary amine groups within the components of the cell wall. However, when immunofluorescence was performed on yeast cells producing either wild-type hENT1, W29T, L442I or W29T/L442I (see Supplementary  Figure 2 at http://www.BiochemJ.org/bj/414/bj4140291add.htm), the average fluorescence intensities per cell were similar for yeast cells producing either hENT1, W29T, L442I or W29T/L442I (P > 0.05), suggesting that these four hENT1 constructs exhibited similar hENT1 expression levels in yeast cells. Additionally, the cellular location of hENT1 appeared to be relatively similar for wild-type hENT1, W29T, L442I and W29T/L442I. Therefore it appeared that the observed changes in V max values were caused by changes in catalytic turnover rates rather than cell-surface abundance.
Bulkier side chains at position 29 of hENT1 markedly increased the apparent K m values for adenosine transport, whereas the absence of a side chain (W29G) or a small side chain (W29A) resulted in less dramatic effects on the apparent K m values. These observations suggest that a tryptophan residue is required for highaffinity adenosine transport, but if the amino acid at position 29 has a small enough side chain, adenosine may be able to interact with another residue, allowing hENT1 to maintain relatively high affinity for adenosine.
The W29T mutation severely compromised the ability of hENT1 to bind and transport pyrimidine nucleosides (Tables 2  and 3 , and Figures 4 and 5) . Interestingly, the multiple sequence alignments presented in Figure 1 revealed that the inosine/guanosine transporter from Leishmania donovani (LdNT2) contains a threonine residue at the corresponding position, suggesting that this residue may be partially responsible for its apparent purine nucleoside selectivity [17] . However, the closely related inosine/guanosine transporter from Crithidia fasciculata (CfNT2) contains an alanine residue at the corresponding position (Figure 1 ) and the W29A hENT1 mutant retained the ability to transport uridine (results not shown), suggesting that this residue does not account for the differences in permeant selectivity between hENT1 and CfNT2 [41] . It has been reported that LdNT1.1 pyrimidine transport is selectively abolished by mutating Gly 183 to alanine, the corresponding residue in LdNT2 and CfNT2 [42] . Therefore it is unlikely that a single residue is responsible for the permeant-selectivity differences between ENT family members, but the data of the present study suggested that the residues corresponding to Trp 29 of hENT1 may play a role in this regard.
The multiple sequence alignments of TM1 (Figure 1 ) revealed that Trp 29 was highly conserved and found in the same TM as Met 33 which was shown previously to be important for inhibitor and permeant interactions [15, 20] . Figure 6 suggested that Trp 29 and Met 33 are in close proximity to one another on the same face of TM1. We have shown previously that when residue 33 of hENT2 was mutated to cysteine, it became sensitive to the membrane impermeable sulfhydryl-reactive agent pchloromercuribenzyl sulfonate in a nucleoside and dipyridamoleprotectable manner [20] . The effects of Trp 29 mutations on adenosine transport efficiency and permeant selectivity shown in the present study, taken together with data on residue 33 reported previously [15, 20] , suggested that the extracellular aspect of TM1 could line the permeant translocation pathway.
The molecular basis whereby a threonine residue at position 29 specifically impaired pyrimidine nucleoside transport activity was unlikely to be related to the effect of Trp 29 mutations on inhibitor interactions. A threonine side chain was specifically required for the loss of pyrimidine nucleoside transport activity, whereas a range of different substitutions at position 29 impaired inhibitor interactions. These results indicate that a tryptophan residue at position 29 is not required for pyrimidine nucleoside transport, but rather that a threonine residue specifically impairs this activity. As such, although this residue may line the permeant translocation pathway, it is unlikely to form a direct contact with pyrimidine nucleosides. W29T may, however, form a hydrogen bond with another residue that is specific and critical for pyrimidine nucleoside interactions without dramatically influencing purine nucleoside transport.
We have reported previously that the L442I mutation in hENT1 resulted in a selective impairment of adenosine transport [21] , whereas in the present study, we demonstrated that this mutation resulted in reduced transport and binding activities of all the purine nucleosides tested (Tables 2 and 3 , and Figures 4 and 5) . It should also be noted that Leu 442 was highly intolerant to mutation, with most amino acid substitutions rendering the transporter non-functional (results not shown), suggesting that a bulky hydrophobic side chain at this position is essential for transport function. Residue 442 may play a critical role in shaping the permeant translocation pathway because the modest change from a leucine side chain to isoleucine impaired translocation of purine nucleosides, whereas all other mutations impaired transport activity completely. Our previous study involving mutations at Met 33 in TM1 and Leu 442 in TM11 suggested that TMs 1 and 11 may be in close proximity to each other in the folded protein because mutations in one TM helix affected the conformation of the other and vice versa in the context of dipyridamole interactions [21] . Thus if TMs 1 and 11 are in close proximity, it is possible that mutations in TM1 affect the conformation of TM11 (and vice versa) and the effects associated with a mutation in one TM may be the indirect consequences of conformational changes in the other TM. However, in the present study, the results shown in Table 3 suggest that the combination of the W29T and L442I mutations had additive effects, presumably because these two residues influenced nucleoside binding and transport independently of one another. Since dipyridamole is structurally larger and more hydrophobic, it is likely that its binding is subject to different conformational influences than that of nucleosides. For example, we have shown previously that, although the L442I mutation is deleterious for adenosine transport, it is more favourable for dipyridamole interactions compared with wild-type hENT1 [21] .
The present study has identified Trp 29 as a previously unrecognized hENT1 residue involved in binding of various ENT inhibitors and physiological nucleosides. Although several studies have identified residues involved in dipyridamole, dilazep and NBMPR interactions, the identification of residues involved in draflazine and soluflazine interactions with hENT1 has not been reported. The helical wheel projection in Figure 6 and the results of the present and previous studies [15, 20, 21] suggest that the extracellular aspect of TM1, on the face containing Trp 29 and Met 33 , forms part of the permeant translocation pathway and may also be part of, or lie close to, the binding sites for nucleoside transport inhibitors. Yeast cells producing wild-type hENT1 (A), W29T (B), L442I (C) or W29T/L442I (D) were examined by immunofluorescence (see [1] for methods) using a monoclonal anti-hENT1 antibody preparation raised against a synthetic peptide located in the large intracellular loop of hENT1 between TMs 6 and 7 (residues 254-273). Fluorescent signals from 100 different cells per hENT1 construct were analysed using Metamorph version 6.1 software and there was no significant difference (P > 0.05) in average fluorescence intensity between yeast cells producing the various hENT1 proteins (E). Fluorescence intensity values were analysed with GraphPad Prism version 4.0 software and are shown as means + − S.E.M.
